Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925).
Détails
ID Serval
serval:BIB_2F30861B4E28
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925).
Périodique
Acta Oncologica
Collaborateur⸱rice⸱s
EORTC Radiation Oncology & Breast Cancer Groups
Contributeur⸱rice⸱s
Poortmans PH., Van Den Bogaert W., Kirkove C., Budach VG., Maingon P., Carla Valli M., Immerzeel JJ., Warlam-Rodenhuis C., Le Pechoux C., Bamberg M., Van Tienhoven G., Glanzmann C., Lutolf UM., Fourquet A., Kuten A., Quetin P., Baeza R., David M., Jobsen J., Sunyach MP., Bartelink H., Russell N., Van Leeuwenhoekziekenhuis A., Mirimanoff RO., Bolla M., Beauduin M., Pfeffer R., Lagrange JL., Dilhuydy JM., Chenal , Benchalal M., Huget P., Courdi A., Bosset JF., Kobierska A., Senkus-Konefka E., Kurtz J., Balmer-Majno S., Koswig S., Krebs H., Bongartz R., Struikmans H., Amalric F., Dolsma WV., Jager JJ., Stellamans K., Guenzi M., Stuschke M., Villa S., Boladeras A., Basic H., Badinez L., Silva I., Muller HM., Strnad V.
ISSN
1651-226X (Electronic)
ISSN-L
0284-186X
Statut éditorial
Publié
Date de publication
2010
Volume
49
Numéro
1
Pages
24-34
Langue
anglais
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
INTRODUCTION: The EORTC 22922/10925 trial investigated the potential survival benefit and toxicity of elective irradiation of the internal mammary and medial supraclavicular (IM-MS) nodes Accrual completed in January 2004 and first results are expected in 2012. We present the toxicity reported until year 3 after treatment.
PATIENTS AND METHODS: At each visit, toxicity was reported but severity was not graded routinely. Toxicity rates and performance status (PS) changes at three years were compared by chi(2) tests and logistic regression models in all the 3,866 of 4,004 patients eligible to the trial who received the allocated treatment.
RESULTS: Only lung (fibrosis; dyspnoea; pneumonitis; any lung toxicities) (4.3% vs. 1.3%; p < 0.0001) but not cardiac toxicity (0.3% vs. 0.4%; p = 0.55) significantly increased with IM-MS treatment. No significant worsening of the PS was observed (p = 0.79), suggesting that treatment-related toxicity does not impair patient's daily activities.
CONCLUSIONS: IM-MS irradiation seems well tolerated and does not significantly impair WHO PS at three years. A follow-up period of at least 10 years is needed to determine whether cardiac toxicity is increased after radiotherapy.
PATIENTS AND METHODS: At each visit, toxicity was reported but severity was not graded routinely. Toxicity rates and performance status (PS) changes at three years were compared by chi(2) tests and logistic regression models in all the 3,866 of 4,004 patients eligible to the trial who received the allocated treatment.
RESULTS: Only lung (fibrosis; dyspnoea; pneumonitis; any lung toxicities) (4.3% vs. 1.3%; p < 0.0001) but not cardiac toxicity (0.3% vs. 0.4%; p = 0.55) significantly increased with IM-MS treatment. No significant worsening of the PS was observed (p = 0.79), suggesting that treatment-related toxicity does not impair patient's daily activities.
CONCLUSIONS: IM-MS irradiation seems well tolerated and does not significantly impair WHO PS at three years. A follow-up period of at least 10 years is needed to determine whether cardiac toxicity is increased after radiotherapy.
Mots-clé
Adult, Aged, Breast Neoplasms/pathology, Breast Neoplasms/radiotherapy, Chemotherapy, Adjuvant, Combined Modality Therapy, Female, Heart/radiation effects, Humans, Lymphatic Metastasis/radiotherapy, Mastectomy, Middle Aged, Neoplasm Staging, Pulmonary Fibrosis/etiology, Radiotherapy/adverse effects, Severity of Illness Index
Pubmed
Web of science
Création de la notice
16/02/2010 11:37
Dernière modification de la notice
20/08/2019 13:13
Données d'usage
